Navigation Links
Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
Date:5/20/2013

we are merging novel pharmacology with local, sustained delivery of drug to the site of disease – an approach that aims to ensure lasting therapeutic effect and systemic safety. We are currently advancing a portfolio of best-in-class drug candidates that have the potential to treat mild, moderate and severe forms of osteoarthritis. Top-line data for FX005, an intra-articular sustained release p38 MAP kinase inhibitor and our lead compound, showed prolonged improvement in joint pain and function throughout the 12-week duration of the Phase 2 study. FX006, an intra-articular sustained release steroid, is currently being evaluated in a Phase 2b dose-ranging study with data expected in the middle of 2013. FX007, an intra-articular sustained release TrkA inhibitor, is being developed to safely address the intractable pain associated with end-stage osteoarthritis.

For more information please visit www.flexiontherapeutics.com.

Editor's Note: Photograph of Frederick Driscoll available on requestMedia ContactsCorporate ContactTony Russo, Ph.D.Lisa Davidson, MBAMatt Middleman, M.D.Vice President, Finance and AdministrationRusso PartnersT: 781-897-9965T: 212-845-425ldavidson@flexiontherapeutics.comT: 212-845-4272 tony.russo@russopartnersllc.com matt.middleman@russopartnersllc.com 
'/>"/>

SOURCE Flexion Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
6. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
7. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
8. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
9. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
10. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
11. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 ... Bio-tech procurement company Amici Procurement has chosen Microsoft ... help it move to Office 365.      ... provides small to medium-sized companies in the bio-tech sector ... aspects of the purchasing cycle to help them obtain ...
(Date:7/1/2015)... RESEARCH TRIANGLE PARK, N.C. and ... -- Leading agricultural research firm AgBiome, and Genective, key ... partnership to accelerate the discovery of new generations ... new traits for insect control to counter the ... to partner with Genective, aligning AgBiome,s unique insect ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... 1, 2015 InferMed , ... will ... evidence-based clinical s olutions suite   ... information products and services, announced today the acquisition of  InferMed ... (CDS) technology company. InferMed,s Arezzo technology supports clinicians ...
Breaking Biology Technology:Biotech Procurement Company Moves to Office 365 with iomart 2AgBiome and Genective collaborate to create novel insect-resistant crops 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... ROCKVILLE, Md., Feb. 10, 2011 Ariadne, a ... today that Georgetown University signed a site license ... continuing its goal of adopting and applying innovative ... Pathway Studio to aid researchers in their efforts ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: ... diverse portfolio of promising hematology and cancer-related products at ... results for the second quarter of fiscal 2011, ended ... of Hematology Annual Meeting in December 2010, we presented ...
... Qteros, Inc., the developer of a unique and ... the lowest-cost production of cellulosic ethanol, today announced a ... Europe for members of its senior management team. ... and Engineering, will present on a panel entitled, "Lessons ...
Cached Biology Technology:Georgetown Lombardi Comprehensive Cancer Center Taps Ariadne for G-DOC Pathway Data and Tools 2Georgetown Lombardi Comprehensive Cancer Center Taps Ariadne for G-DOC Pathway Data and Tools 3YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 2YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 3YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 4YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 5YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 6YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 7YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 8YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results 9Qteros Management to Present at Notable Alternative Energy Conferences in February 2
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... 2015 Research and ... the "Huawei Ascend Mate 7 Fingerprint Sensor ... offering. Huawei,s technological choice for the ... than Apple,s and Samsung,s one. The Ascend Mate ... Fingerprint Cards, a main actor in capacitive sensing ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... In a study to be published in the journal ... cyclin A plays an important but previously unknown role in ... ensure the faithful segregation of chromosomes during cell division. , ... splitting into two identical copies. This process happens trillions of ...
... WATERLOO, Ont. (Wednesday, September 11, 2013) A tiny number ... fish in the Great Lakes, according to new research from ... journal Biological Invasions , research from Professor Kim Cuddington ... probability of Asian carp establishment soars with the introduction of ...
... The NTA IPM team has significantly enhanced the environmental ... research and outreach information needed by scientific and regulatory ... crops to beneficial non-target arthropods. Each year the Entomological ... which includes at least one entomologist from the private ...
Cached Biology News:Discovery of cell division 'master controller' may improve understanding and treatment of cancer 2Tiny number of Asian carp could be big problem for the Great Lakes 2Risk assessment team on Bt plants wins Integrated Pest Management Award 2
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...
... size markers are a mixture of Strep•Tag® ... 100 kDa. The markers provide precise size ... staining with Coomassie blue. Because each of ... the markers can also be detected by ...
Biology Products: